Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valneva SECHIX:VLAP 64 Equity-to-Asset is 0.21 as of Mar. 2026, which is 43% below its 10-year median of 0.37. GuruFocus rates CHIX:VLAP with a GF Score™ of 64/100 and a GF Value™ of €2.52 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Valneva SE ranks worse than 81.99% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Valneva SE's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €76.7 Mil. Valneva SE's Total Assets for the quarter that ended in Mar. 2026 was €372.0 Mil.
Therefore, Valneva SE's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.21.
The historical rank and industry rank for Valneva SE's Equity-to-Asset or its related term are showing as below:
CHIX:VLAp'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09 Med: 0.37 Max: 0.62
Current: 0.21
During the past 13 years, the highest Equity to Asset Ratio of Valneva SE was 0.62. The lowest was 0.09. And the median was 0.37.
CHIX:VLAp's Equity-to-Asset is ranked worse than 81.99% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs CHIX:VLAp: 0.21
Valneva SE (CHIX:VLAp) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Valneva SE Equity-to-Asset Related Terms
Valneva SE Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Valneva SE's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VLAP vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Valneva SE's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valneva SE Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valneva SE's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Valneva SE's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Valneva SE's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (CHIX:VLAP) has a Equity-to-Asset of 0.21 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valneva SE and its competitors. This is 43% below median its historical median of 0.37. Over the past decade, Valneva SE's Equity-to-Asset has ranged from 0.09 to 0.62. According to the industry distribution chart, Valneva SE ranks #1161 out of 1416 companies in the Biotechnology industry, placing it in the top 82%.
Is Valneva SE's Equity-to-Asset too high?
Valneva SE's current Equity-to-Asset of 0.21 is 43% below median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.62. The Biotechnology industry median Equity-to-Asset is 0.68. Valneva SE's value of 0.21 is 69.1% below this industry median. Based on the distribution chart, Valneva SE ranks #1161 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valneva SE has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #1161 out of 1416 companies for Equity-to-Asset. This places Valneva SE in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Valneva SE's value of 0.21 is 69.1% below this benchmark. Historically, Valneva SE's own Equity-to-Asset has ranged from 0.09 to 0.62 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 0.68, Valneva SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current Equity-to-Asset of 0.21 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valneva SE and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current Equity-to-Asset is 0.21, which is 43% below median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (CHIX:VLAP) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.24 — trading 11.1% below its estimated fair value. The current Equity-to-Asset is 0.21, which is 43% below median its 10-year median of 0.37 and 69.1% below the Biotechnology industry median of 0.68. Valneva SE's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Valneva SE (CHIX:VLAP), the current Equity-to-Asset is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (CHIX:VLAP) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.24 is trading 11.1% below its estimated GF Value™ of €2.52.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for CHIX:VLAP:
Equity-to-Asset: 0.21 (43% below median its 10-year median of 0.37)
GF Value™: €2.52 vs. price of €2.24 (11.1% below fair value)
Industry Position: 69.1% below the Biotechnology median (#1161 of 1416)
No single metric tells the full story. See the CHIX:VLAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
64GF Score
Get the complete analysis for CHIX:VLAP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VLAP has been successfully added to your 
